Influenza Medication Market - Global Forecast 2026-2032

The influenza medication market is undergoing significant evolution, shaped by advances in drug innovation, the expansion of digital distribution channels, and adaptive operational strategies. These changes present healthcare executives with opportunities to address evolving therapeutic and commercial priorities effectively.

Market Snapshot: Influenza Medication Market Growth and Outlook

The Influenza Medication Market is projected to expand from USD 3.79 billion in 2025 to USD 3.99 billion by 2026, maintaining a CAGR of 5.44% and reaching USD 5.49 billion by 2032. This growth reflects a robust demand environment, with therapeutic advances and digital transformation fueling expanded access and product adoption. Real-time fulfillment, innovative delivery models, and operational flexibility are driving increased adoption across established and emerging healthcare systems.

Scope & Segmentation in the Influenza Medication Market

This report delivers an actionable segmentation analysis, clarifying what drives product differentiation, value-chain optimization, and competitor positioning:

Route of Administration: Inhalation, intravenous, and oral forms (suspension and tablet), each entailing distinct requirements for clinical application, patient experience, and logistics.
Formulation Types: Injectable, powder inhaler, suspension, and tablet options influence factors such as manufacturability, storage needs, and adherence strategies, especially around cold chain management.
Therapeutic Mechanisms: Endonuclease inhibitors, M2 ion channel inhibitors, and neuraminidase inhibitors, each relevant to resistance management, regulatory compliance, and clinical protocols.
Distribution Channels: Hospital pharmacies (meeting sterile handling needs for severe cases), retail pharmacies (offering broad community access), and online pharmacies (enabling digital fulfillment and enhanced patient support).
End-User Delivery: Outpatient clinics, hospital networks, and home-care environments, each contributing to preferred dosage forms, packaging requirements, and patient service configurations.
Regions Covered: Americas, Europe, Middle East & Africa, and Asia-Pacific. Regulatory, operational, and market-entry dynamics shape strategic approaches in each geography, offering unique challenges and pathways to commercialization.

Key Takeaways for Senior Decision-Makers

Ongoing scientific developments are broadening therapeutic choices, requiring nimble R&D planning and targeted evidence generation to sustain value in dynamic care settings.
The rise of digital channels, including telehealth and online pharmacies, is accelerating product access and creating differentiation in patient services and fulfillment models.
Strengthening supply-chain processes through diversified sourcing and strategic inventory management remains essential to mitigate external disruption risks.
Regional variation in regulatory frameworks and payer policies demands a flexible approach to commercialization and reimbursement planning.
Manufacturers with adaptable, scalable operations better navigate shifts in policy and support access across diverse patient care modalities.
Integrated market segmentation—linking product attributes and delivery strategies to end-user preferences—enables the provision of clinically meaningful and commercially sustainable solutions.

Tariff Impact: United States Policy Developments

Recent changes in United States tariffs on select pharmaceutical ingredients have heightened complexity in sourcing and distribution. In response, manufacturers are widening their supplier bases, adopting regional contract manufacturing, and enhancing local production capacity for antiviral components. This evolving environment emphasizes the necessity for improved supply chain transparency, contingency inventory planning, and tighter alignment between procurement and manufacturing. Hospital and payer decision-making increasingly prioritizes resilience and security of supply over short-term savings as trade realities reshape operational priorities. The shift toward regional partnerships and manufacturing localization exemplifies industry adaptation strategies.

Methodology & Data Sources

This analysis is grounded in primary interviews with clinicians, procurement leaders, distribution professionals, and supply chain experts. Regulatory specialists and payer input ensured that procurement and evidence requirements were considered. Secondary research drew on peer-reviewed articles, industry disclosures, and regulatory guidance. Scenario mapping alongside thematic review informed final recommendations and validated key findings.

Why This Report Matters

Assists senior leaders in aligning R&D, production, and distribution strategies to match changing market conditions and shifting clinical practices.
Informs investment decisions in digital platforms and supply-chain resilience to mitigate operational risks and policy shifts.
Enables development of tailored regional approaches, supporting effective product launches and market expansion in a dynamic international landscape.

Conclusion

Innovation, digital adoption, and policy shifts continue to redefine the influenza medication landscape. A well-integrated approach, connecting clinical, operational, and distribution priorities, is essential for maintaining access and commercial progress in this competitive and evolving market environment.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Influenza Medication Market, by Form

8.1. Injection
8.2. Powder Inhaler
8.3. Suspension
8.4. Tablet
8.4.1. Amantadine
8.4.2. Baloxavir Marboxil
8.4.3. Oseltamivir
8.4.4. Rimantadine

9. Influenza Medication Market, by Route Of Administration

9.1. Inhalation
9.2. Intravenous
9.3. Oral
9.3.1. Suspension
9.3.2. Tablet

10. Influenza Medication Market, by Drug Class

10.1. Endonuclease Inhibitors
10.2. M2 Ion Channel Inhibitors
10.2.1. Amantadine
10.2.2. Rimantadine
10.3. Neuraminidase Inhibitors
10.3.1. Oseltamivir
10.3.2. Peramivir
10.3.3. Zanamivir

11. Influenza Medication Market, by End User

11.1. Home Care
11.2. Hospitals
11.3. Outpatient Clinics

12. Influenza Medication Market, by Distribution Channel

12.1. Hospital Pharmacy
12.2. Online Pharmacy
12.3. Retail Pharmacy

13. Influenza Medication Market, by Region

13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific

14. Influenza Medication Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Influenza Medication Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. United States Influenza Medication Market
17. China Influenza Medication Market

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abbott Laboratories
18.6. Agilent Technologies, Inc.
18.7. AstraZeneca PLC
18.8. Bio-Rad Laboratories, Inc.
18.9. Bristol-Myers Squibb Company
18.10. Cocrystal Pharma, Inc.
18.11. CSL Limited
18.12. Daiichi Sankyo Company, Limited
18.13. Eli Lilly and Company
18.14. F. Hoffmann-La Roche AG
18.15. GlaxoSmithKline PLC
18.16. Lupin Limited
18.17. Merck & Co., Inc.
18.18. NATCO Pharma Limited
18.19. Novartis AG
18.20. Pfizer Inc.
18.21. Qiagen N.V.
18.22. Sandoz International GmbH
18.23. Sanofi SA
18.24. Shionogi & Co., Ltd.
18.25. Sun Pharmaceutical Industries Ltd.
18.26. Takeda Pharmaceutical Company Limited
18.27. Teva Pharmaceutical Industries Ltd.
18.28. Viatris Inc.
18.29. Zydus Pharmaceuticals, Inc.

List of Figures

FIGURE 1. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 133. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 135. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 136. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 137. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 138. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 139. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 140. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 141. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 147. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 148. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 155. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 156. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 157. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 158. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 159. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 160. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 161. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 162. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 174. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 176. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 177. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 178. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 179. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 180. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 181. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 182. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. GCC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 185. GCC INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 186. GCC INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 187. GCC INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 188. GCC INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 189. GCC INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 190. GCC INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 191. GCC INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 192. GCC INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. GCC INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. BRICS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. BRICS INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 206. BRICS INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 207. BRICS INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 208. BRICS INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 209. BRICS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 210. BRICS INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 211. BRICS INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 212. BRICS INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. BRICS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 214. G7 INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 215. G7 INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 216. G7 INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 217. G7 INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 218. G7 INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 219. G7 INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 220. G7 INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 221. G7 INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 222. G7 INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 223. G7 INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 224. NATO INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 225. NATO INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 226. NATO INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 227. NATO INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 228. NATO INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 229. NATO INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 230. NATO INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 231. NATO INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 232. NATO INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 233. NATO INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 234. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 236. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 237. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 238. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 239. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 240. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 241. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 242. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 243. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 245. CHINA INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 246. CHINA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 247. CHINA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 248. CHINA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 249. CHINA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 250. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 251. CHINA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 252. CHINA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 253. CHINA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 254. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Influenza Medication market report include:

Abbott Laboratories
Agilent Technologies, Inc.
AstraZeneca PLC
Bio-Rad Laboratories, Inc.
Bristol-Myers Squibb Company
Cocrystal Pharma, Inc.
CSL Limited
Daiichi Sankyo Company, Limited
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Lupin Limited
Merck & Co., Inc.
NATCO Pharma Limited
Novartis AG
Pfizer Inc.
Qiagen N.V.
Sandoz International GmbH
Sanofi SA
Shionogi & Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Viatris Inc.
Zydus Pharmaceuticals, Inc.

Table Information

Report Attribute	Details
No. of Pages	186
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 3.99 Billion
Forecasted Market Value ( USD ) by 2032	$ 5.49 Billion
Compound Annual Growth Rate	5.4%
Regions Covered	Global
No. of Companies Mentioned	26

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3513EUR$3,939USD£3,046GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3789EUR$4,249USD£3,285GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5136EUR$5,759USD£4,453GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6215EUR$6,969USD£5,389GBP

Market Snapshot: Influenza Medication Market Growth and Outlook

Scope & Segmentation in the Influenza Medication Market

Key Takeaways for Senior Decision-Makers

Tariff Impact: United States Policy Developments

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Influenza Medication - Global Strategic Business Report

Influenza Treatment Market Report 2025

Influenza Drug Market Report 2025

Influenza Treatment Market Outlook 2025-2034: Market Share, and Growth Analysis

Bird Flu Treatment Market - Global Forecast 2026-2032